Search the University of Manchester siteSearch Menu StaffNet
Search type

ADAPT

Trial Name: BiomArker-guided Duration of Antibiotic treatment in hospitalised PaTients with moderate to severe Sepsis

Chief Investigator: Professor Paul Dark

Trial Description: A Phase IV, randomised, multicentre study

Background: Sepsis is linked to long term illness and unavoidable deaths, with the NHS providing a generic antibiotic treatment plan. Increases in the biomarkers C-reactive protein (CRP) and procalcitonin (PCT) are linked with sepsis, providing an opportunity for a targeted, antibiotic duration plan to reduce patient side effects and overall antibiotic usage.

Main Outcomes: To determine whether monitoring of CRP or PCT as a treatment plan reduces the duration of guided antibiotic therapy in patients with moderate to severe sepsis compared to standard care.

Patients to be recruited: 1000+

Status: Set-up

CTU: Warwick

Funder: National Institute for Health Research (Health Technology Assessment)

Further Information: paul.m.dark@manchester.ac.uk